Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest www.briantempest.com Generics & Biosimilars, CpHI Conference Istanbul,

Slides:



Advertisements
Similar presentations
Australian Centre for Innovation Mid-Year Report 2014 Professor Ron Johnston, FTSE, FRSN Australian Centre for Innovation Addressing the challenges of.
Advertisements

South Asian Pharmaceutical Council
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace: an India-China Emerging World Webcast Dr. Brian W Tempest
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest UK 18,19,20 March 2014.
Hale & Tempest Understanding the Strategies Big Pharma are Developing to win in the Global Generics Market Dr. Brian W Tempest Istanbul,
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
The Contribution of African Women to Economic Growth and Development: Historical Perspectives and Policy Implications Chair Dr. Rosati Mokate was appointed.
Hale & Tempest Strategic Pharma Issues Dr. Brian W Tempest Mumbai, India May 2013.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest 9 th Annual Global Generic.
Premium Finance Strategies for Single Life and Survivorship.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
Hale & Tempest The Sustainability of Generics Dr. Brian W Tempest Centre for Doctoral Training in Healthcare, University of Oxford,
Hale & Tempest Distribution, OTC & CRAMS Chesapeake Dr. Brian W Tempest UK March 2014.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Hale & Tempest Moving Beyond the Commodity Market: What Future is there in added Value Generics, Niche Products and Biosimilars? Dr. Brian W Tempest
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
Global Medical Membrane Market: Industry Analysis, Trend and Growth, by Future Market Insights
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
1 Institute of Company Secretaries, India Keynote address : corporate governance + globalisation + the board Hong Kong, China 12 May 2008 Fianna Jesover.
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st.
Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011.
UPDATE ON NEXIA ASIA PACIFIC Presented by: Henry SK Tan Board Member & Asia Pacific Regional Chairman, Nexia International Managing Director, Nexia TS.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest MAPE Fund Managers Conference.
2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.
Hale & Tempest A View from India Dr. Brian W Tempest Opinion Formers’ Conference on Intellectual Property for Better Health Wellcome.
Hale & Tempest Strategic Pharma Issues Dr. Brian W Tempest Mumbai, India January 2013.
Hale & Tempest How to provide affordable medicines in today’s competitive Global Market Dr. Brian W Tempest
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest The Sustainability of the Generics Industry – rethinking the future Dr. Brian W Tempest World Generics Congress, London,
Hale & Tempest Global Generics & Companies Chesapeake Dr. Brian W Tempest UK March 2014.
Entertainment Mid Range Plan Strategy Towards Emerging Market Sony Corp. Corporate Planning & Control Division September 30, 2010.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Indian Drug Discovery Dr. Brian W Tempest Asia Pacific Technology Network Tuesday 3 April 2012.
Hale & Tempest Doing Business in Russia - the View from Overseas Dr. Brian W Tempest CpHI St Petersburg, Russia 17 April 2014.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
1 World Regions. 1 Southeast Asia 2 World Regions.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Candidacy for IEEE President-elect 2013 Tariq S Durrani To IEEE Region 1 18 August 2012.
Hale & Tempest Consultation of Experts to discuss the WHO role in facilitating access to quality, affordable biotherapeutics (monoclonal antibodies & biosimilars.
The Providence Group.
The Global Think Tank January CARNEGIE’S FOUNDING “…to advance the cause of peace among nations; to hasten the renunciation of war as an instrument.
Hale & Tempest Patents & Health Dr. Brian W Tempest Seminar on the Relationship between Patent Systems and the Availability of Medicines.
The Ranbaxy deal By Jithin Manohar. Scenario at the Time of Acquisition ‘ India held US $7.5 billion of the $550 billion of the global pharmaceutical.
Hale & Tempest Biosimilars in Developing Countries: Key Issues Dr. Brian W Tempest Editor, Journal of Generic Medicines Bangladesh.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Bioabsorbable Vascular Stents Market Share, Segmentation, Report 2024.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
International Business School Shanghai Conference – October 18th 2016
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
Address to the IEEE Region 10 Leadership IEEE Region 10 Meeting
Biosimilars in Developing Countries: Key Issues
Databridgemarketresearch.comdatabridgemarketresearch.com US : UK :
CIPS GLOBAL REACH STRATEGY
As this timeline shows, Nadcap began in 1990 with US aerospace prime contractors as subscribers. Within 5 years, European companies were signing up and.
Toronto: Regional Director North America
Intl Director of Campaigns Director of Policy & External Affairs
Middle East ____________
Religare Health Insurance Company Limited
Global Aluminum Product Manufacturing From Purchased Aluminum Market Report © The Business Research Company. All rights reserved.
As this timeline shows, Nadcap began in 1990 with US aerospace prime contractors as subscribers. Within 5 years, European companies were signing up and.
Global 3D cell culture market
Presentation transcript:

Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul, Turkey 19 September 2012

Hale & Tempest Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets, a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd

Hale & Tempest The Future??

Hale & Tempest Mylan won’t follow “irrational behavior” Source : Generics Bulletin 5 August 2011

Hale & Tempest Biologics in 2016 Source: Cowen

Hale & Tempest Thank You